Table 2.
Anatomical and functional parameters during the follow-up.
| Variable | Baseline | 60 days | 120 days | 150 days | p-value* |
|---|---|---|---|---|---|
| BCVA (logMar) | 0.5 (0.3–0.6) | 0.4 (0.3–0.5)‡ | 0.3 (0.3–0.5) | 0.3 (0.2–0.5) | <0.001 |
| CMT (µm) | 429.5 (371.0–599.0) | 307.0 (275.0–365.0) | 261.0 (239.0–283.0) | 256.0 (203.0–280.0) | 0.003 |
| Foveal SCPD (µm) | 27.5 (19.0–31.0) | 25.5 (22.0–30.4) | 25.0 (20.0–32.0) | 27.4 (17.2–32.3) | 0.256 |
| Parafoveal SCPD (µm) | 40.0 (38.0–46.0) | 45.0 (42.0–47.0) | 45.5 (43.0–48.0) | 46.4 (44.6–49.2) | <0.001 |
| Foveal DCPD (µm) | 21.0 (12.0–25.0) | 25.0 (20.0–26.0)† | 30.0 (14.0–35.0) | 26.5 (19.7–34.9) | 0.050 |
| Parafoveal DCPD (µm) | 48.5 (43.0–51.0) | 48.5 (45.0–55.0)† | 51.5 (49.0–52.0) | 51.8 (50.3–53.4) | 0.019 |
| Foveal CCD (µm) | 63.0 (59.5–66.3) | 63.5 (57.0–65.0) | 62.0 (59.0–64.0) | 66.6 (63.8–66.9) | 0.061 |
| Parafoveal CCD (µm) | 63.0 (61.8–65.3) | 63.5 (62.0–65.0) | 65.0 (64.0–67.0) | 66.2 (64.9–67.9) | 0.085 |
*Friedman test evaluating variation in anatomical and functional parameter among time; †p < 0.05, ‡p < 0.001 pairwise post-hoc analysis vsprevious measurement.
Bolded p-value were significant after FDR correction.
Abbreviations: BCVA = best corrected visual acuity, CMT = central macular thickness; SCPD = superior capillary plexus density;
DCPD = deep capillary plexus density; CCD = choriocapillaris density.